Analysts Anticipate Bio-Path Holdings Inc (NASDAQ:BPTH) Will Post Earnings of -$0.79 Per Share

Share on StockTwits

Analysts expect Bio-Path Holdings Inc (NASDAQ:BPTH) to report earnings of ($0.79) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Bio-Path’s earnings. The company is expected to announce its next earnings report on Wednesday, March 18th.

On average, analysts expect that Bio-Path will report full year earnings of ($3.30) per share for the current year. For the next financial year, analysts expect that the firm will report earnings of ($3.29) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Bio-Path.

A number of brokerages have recently issued reports on BPTH. HC Wainwright restated a “buy” rating and issued a $25.00 target price (down previously from $28.00) on shares of Bio-Path in a research note on Monday. ValuEngine downgraded Bio-Path from a “buy” rating to a “hold” rating in a research note on Tuesday.

BPTH stock opened at $7.30 on Friday. The firm has a market cap of $20.91 million, a P/E ratio of -0.51 and a beta of 3.05. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.85 and a current ratio of 13.85. The stock has a 50-day simple moving average of $10.22 and a 200-day simple moving average of $12.04. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52.

Several hedge funds and other institutional investors have recently modified their holdings of BPTH. Vanguard Group Inc. lifted its stake in Bio-Path by 10.3% during the second quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock worth $374,000 after purchasing an additional 2,601 shares during the last quarter. BlackRock Inc. increased its position in Bio-Path by 17.5% in the 2nd quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock valued at $628,000 after acquiring an additional 6,978 shares during the period. Finally, Morgan Stanley increased its position in Bio-Path by 19,858.0% in the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after acquiring an additional 19,858 shares during the period. Institutional investors and hedge funds own 6.13% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Story: What is the return on assets (ROA) ratio?

Get a free copy of the Zacks research report on Bio-Path (BPTH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.